◎ Sugi Atlas

Atlas / Drug / Emactuzumab

Emactuzumab

drug
On this page

Also known as 7i1955n5wxCXD-301CXD301RG-7155RG7155RO-5509554RO5509554RO5509554 (ANTI-CSF-R1)

Summary

Emactuzumab (CHEMBL3545370) is a phase-3 clinical-stage antibody targeting CSF1R; indicated across 4 conditions including neoplasm and tenosynovial giant cell tumor, diffuse type.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Antibody
  • Targets: 1 (CSF1R)
  • Indications: 4 conditions
  • Clinical trials: 7

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3545370
NameEmactuzumab
TypeAntibody
Max phase3

Also known as: 7i1955n5wx, CXD-301, CXD301, Emactuzumab, RG-7155, RG7155, RO-5509554, RO5509554, RO5509554 (ANTI-CSF-R1), EMACTUZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
CSF1Rcolony stimulating factor 1 receptorBinding9.540%P07333

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CSF1R.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Other interleukin signaling1CSF1R
Transcriptional Regulation by VENTX1CSF1R
Signaling by CSF1 (M-CSF) in myeloid cells1CSF1R

Dominant GO biological processes

GO termTargets
positive regulation of protein phosphorylation1
response to ischemia1
inflammatory response1
signal transduction1
cell surface receptor protein tyrosine kinase signaling pathway1
axon guidance1
cell population proliferation1
positive regulation of cell population proliferation1
negative regulation of cell population proliferation1
regulation of cell shape1
positive regulation of macrophage chemotaxis1
cell migration1
peptidyl-tyrosine phosphorylation1
cytokine-mediated signaling pathway1
olfactory bulb development1

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
neoplasm3MONDO:0005070EFO:0000616
tenosynovial giant cell tumor, diffuse type3MONDO:0024686MONDO:0024686
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

PhaseTrials
PHASE14
PHASE32
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03768063PHASE3ACTIVE_NOT_RECRUITINGA Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT05417789PHASE3ACTIVE_NOT_RECRUITINGStudy of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
NCT02923739PHASE2TERMINATEDPaclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01494688PHASE1COMPLETEDA Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
NCT02323191PHASE1COMPLETEDA Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
NCT02760797PHASE1COMPLETEDA Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
NCT03369964PHASE1WITHDRAWNA Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

72 molecules share ≥1 primary target. Top 72 by shared-target count:

MoleculeSourceStatusShared targets
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)CSF1R
PAZOPANIBChEMBL + PubChemPhase 4 (approved)CSF1R
AXITINIBChEMBLPhase 4 (approved)CSF1R
BOSUTINIBChEMBLPhase 4 (approved)CSF1R
BRIGATINIBChEMBLPhase 4 (approved)CSF1R
DASATINIBChEMBLPhase 4 (approved)CSF1R
ENTRECTINIBChEMBLPhase 4 (approved)CSF1R
FEDRATINIBChEMBLPhase 4 (approved)CSF1R
FILGOTINIBChEMBLPhase 4 (approved)CSF1R
IBRUTINIBChEMBLPhase 4 (approved)CSF1R
IMATINIBChEMBLPhase 4 (approved)CSF1R
MIDOSTAURINChEMBLPhase 4 (approved)CSF1R
NERATINIBChEMBLPhase 4 (approved)CSF1R
NILOTINIBChEMBLPhase 4 (approved)CSF1R
NINTEDANIBChEMBLPhase 4 (approved)CSF1R
PACRITINIBChEMBLPhase 4 (approved)CSF1R
PEXIDARTINIBChEMBLPhase 4 (approved)CSF1R
PONATINIBChEMBLPhase 4 (approved)CSF1R
QUIZARTINIBChEMBLPhase 4 (approved)CSF1R
SORAFENIBChEMBLPhase 4 (approved)CSF1R
SUNITINIBChEMBLPhase 4 (approved)CSF1R
SUNITINIB MALATEChEMBLPhase 4 (approved)CSF1R
VANDETANIBChEMBLPhase 4 (approved)CSF1R
ALVOCIDIBChEMBLPhase 3CSF1R
BRIVANIBChEMBLPhase 3CSF1R
CEDIRANIBChEMBLPhase 3CSF1R
DACTOLISIBChEMBLPhase 3CSF1R
DOVITINIBChEMBLPhase 3CSF1R
LESTAURTINIBChEMBLPhase 3CSF1R
LINIFANIBChEMBLPhase 3CSF1R
MASITINIBChEMBLPhase 3CSF1R
MOTESANIBChEMBLPhase 3CSF1R
PIMICOTINIBChEMBLPhase 3CSF1R
SEMAXANIBChEMBLPhase 3CSF1R
VATALANIBChEMBLPhase 3CSF1R
VIMSELTINIBChEMBLPhase 3CSF1R
ARRY-382ChEMBLPhase 2CSF1R
BELVARAFENIBChEMBLPhase 2CSF1R
BMS-754807ChEMBLPhase 2CSF1R
CC-115ChEMBLPhase 2CSF1R
CENISERTIBChEMBLPhase 2CSF1R
CEP-11981ChEMBLPhase 2CSF1R
CEP-32496ChEMBLPhase 2CSF1R
CERDULATINIBChEMBLPhase 2CSF1R
DEFOSBARASERTIBChEMBLPhase 2CSF1R
DERAZANTINIBChEMBLPhase 2CSF1R
DORAMAPIMODChEMBLPhase 2CSF1R
EDICOTINIBChEMBLPhase 2CSF1R
ELZOVANTINIBChEMBLPhase 2CSF1R
ENMD-2076ChEMBLPhase 2CSF1R
ENRUPATINIBChEMBLPhase 2CSF1R
FORETINIBChEMBLPhase 2CSF1R
GZ-389988ChEMBLPhase 2CSF1R
ILORASERTIBChEMBLPhase 2CSF1R
INIXACICLIBChEMBLPhase 2CSF1R
NARAZACICLIBChEMBLPhase 2CSF1R
NEFLAMAPIMODChEMBLPhase 2CSF1R
ONATASERTIBChEMBLPhase 2CSF1R
PELITINIBChEMBLPhase 2CSF1R
R-406ChEMBLPhase 2CSF1R
RAF-265ChEMBLPhase 2CSF1R
REBASTINIBChEMBLPhase 2CSF1R
SEGIGRATINIBChEMBLPhase 2CSF1R
SOTULETINIBChEMBLPhase 2CSF1R
SU-014813ChEMBLPhase 2CSF1R
TANDUTINIBChEMBLPhase 2CSF1R
TOZASERTIBChEMBLPhase 2CSF1R
AfatinibPubChemApprovedCSF1R
GefitinibPubChemApprovedCSF1R
IdelalisibPubChemApprovedCSF1R
regorafenibPubChemApprovedCSF1R
SelumetinibPubChemApprovedCSF1R

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot